Mandate

Vinge advises Vimian in connection with new RCF and issuance of senior unsecured bonds

May 28, 2025 Banking and Finance

Vinge advises Vimian Group AB (publ) (“Vimian”) in connection with a new EUR 330 million multicurrency revolving facility agreement and its issuance of senior unsecured bonds in an amount of EUR 150 million (within a framework of EUR 250 million)

The revolving credit facility and the proceeds from the bonds will be used, inter alia, to refinance Vimian’s existing multicurrency term and revolving facilities agreement and to finance general corporate purposes.

The credit facility, arranged by Nordea Bank Abp, filial i Sverige, DNB Bank ASA, Sweden Branch and Skandinaviska Enskilda Banken AB (publ), consists of a multicurrency revolving credit facility of EUR 330,000,000 (with an up to EUR 100,000,000 uncommitted incremental facility). The agreement has a three-year term, with the possibility of an extension.

The bonds have a tenor of three years and were issued with a coupon of EURIBOR 3m plus 200 basis points. The bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm. DNB Carnegie Investment Bank AB (publ), Nordea Bank Abp, and Skandinaviska Enskilda Banken AB (publ) acted as joint bookrunners in connection with the bond issuance.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. Vimian’s shares are listed on Nasdaq Stockholm.

  

Vinge’s team consisted of Albert Wållgren, Linn Adelwald, Lionardo Ojeda and William Carlberg Johansson.

 

Related

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025